Written by the Nuvirox Research Team
Key Points
- A mouse study found topical NMN reduced eczema-like symptoms, inflammation, and water loss through the skin barrier.
- This research used topical application on mice, not oral supplementation, and hasn't been tested in a human eczema trial.
- Standard eczema management — moisturizers, topical steroids where needed, and trigger avoidance — has far deeper human evidence.
Short answer: there's a genuine, mechanistically interesting mouse study showing topical NMN calms eczema-like skin inflammation — but it's topical, not oral, and it's mice, not people, so it doesn't support an oral NAD+ supplement as an eczema treatment. This is a useful topic for understanding how easily preclinical skin research gets stretched into oral-supplement marketing claims that go beyond what was actually tested.
Why NAD+ is connected to skin barrier function
Atopic dermatitis (eczema) involves a disrupted skin barrier that allows excess water loss and lets irritants and allergens penetrate more easily, combined with an overactive immune and inflammatory response in the skin. Oxidative stress (excess reactive oxygen species, or ROS) is known to worsen both the barrier disruption and the inflammation in eczema. Because NAD+ is central to cellular antioxidant defenses, researchers have looked at whether boosting NAD+ locally in skin tissue could calm this cycle.
What the mouse study actually found
A study published in International Immunopharmacology in 2022 induced atopic-dermatitis-like skin lesions in mice using a chemical irritant (DNFB), then applied nicotinamide mononucleotide (NMN) topically to the affected skin for two weeks. The results were genuinely positive within this model: NMN reduced the dermatitis severity score, reduced itching behavior, reduced transepidermal water loss (a direct measure of skin barrier function), and restored the expression of skin barrier genes that are normally disrupted in eczema. Mechanistically, the researchers traced this to NMN blocking a specific inflammatory signaling pathway (ROS-mediated JAK2/STAT5) that drives much of the tissue damage in atopic dermatitis.
Study Snapshot — Gao et al., Int Immunopharmacol 2022
| Model | Mice, DNFB-induced atopic dermatitis |
| Intervention | Topical NMN, 2 weeks |
| Findings | Reduced dermatitis score, itching, water loss; restored barrier gene expression |
| Route tested | Topical only — not oral |
| Human trial exists? | No |
Why "topical NMN in mice" doesn't equal "oral NAD+ supplement for your eczema"
This is worth spelling out clearly, because it's an easy place for marketing to overreach. The study applied NMN directly onto the skin of mice — a completely different route of exposure than swallowing an oral NR or NMN capsule, which gets absorbed through the gut and processed by the liver before reaching general circulation, let alone skin tissue at meaningful concentrations. An oral supplement is not designed or expected to deliver NAD+ precursors to skin tissue the way a topical application does. Separately, mice are not people, and no eczema-specific human trial has tested either topical or oral NAD+ precursors. Both gaps — route of administration and species — need to close before this becomes a claim that applies to you taking a capsule.
What actually has strong evidence for eczema
Regular use of moisturizers (emollients) is one of the best-evidenced, foundational treatments for eczema and dry skin generally. Topical corticosteroids remain the mainstay for flare-ups, with topical calcineurin inhibitors as an alternative for sensitive areas. For more severe cases, newer targeted therapies (like dupilumab, a biologic medication) have strong randomized trial evidence. Identifying and avoiding personal triggers — certain fabrics, harsh soaps, extreme temperatures — is a reasonable, low-risk supportive measure alongside medical treatment.
What NAD+ won't do for eczema right now
Based on current evidence, an oral NAD+ precursor supplement should not be expected to improve eczema or general dry skin — that specific claim hasn't been tested, and the positive finding that does exist used a completely different route of delivery in a different species. If eczema is significant, persistent, or affecting your sleep or quality of life, a dermatologist can offer treatments with real trial support behind them.
What about oral NAD+ precursors and skin aging more broadly?
It's worth separating this from a related but distinct topic: general skin aging. Some cosmetic research has looked at topical NMN formulations for wrinkles, puffiness, and dark circles, using small human cosmetic trials rather than eczema-specific medical trials. That's a different question from eczema treatment, uses a different formulation and endpoint, and shouldn't be conflated with the barrier-repair findings discussed above. If skin aging, rather than eczema specifically, is your interest, that deserves its own separate look at the evidence rather than borrowing conclusions from the eczema mouse study.
What's actually in the skin barrier that gets disrupted
It helps to understand what "skin barrier" actually refers to when eczema research talks about it. The outermost layer of skin relies on specific structural proteins (like filaggrin) and lipids arranged in an orderly pattern to keep water in and irritants out; in eczema, both genetic factors (some people carry filaggrin gene mutations) and ongoing inflammation disrupt this structure, creating a cycle where a weaker barrier lets in more irritants, which triggers more inflammation, which weakens the barrier further. The mouse study discussed above found that topical NMN helped restore expression of some of these barrier-related genes, which is mechanistically consistent with the transepidermal water loss improvements the researchers measured — a coherent, if still preclinical, story.
Frequently asked questions
Would a topical NAD+ cream help my eczema?
The mouse research is promising enough to be a legitimate area for future human trials, but no topical NAD+ or NMN product has been tested in a published human eczema trial. It's an interesting research direction, not yet a proven treatment.
Does taking an oral NAD+ supplement do anything for skin barrier function?
This hasn't been directly tested for eczema. Oral NAD+ precursors raise systemic NAD+ levels gradually, which is a different exposure than the direct topical application used in the mouse study discussed here.
What's the single most useful thing I can do for dry, eczema-prone skin?
Consistent use of a fragrance-free moisturizer, especially right after bathing, is one of the most consistently evidence-backed habits for eczema and dry skin. A dermatologist can help build out a full plan from there.
When should eczema be evaluated by a doctor?
If it's widespread, not responding to over-the-counter moisturizers, showing signs of infection (increased redness, warmth, pus), or significantly affecting sleep or daily life, a dermatologist visit is worthwhile.
FROM NUVIROX
Why we formulated NAD+ Restore
NAD+ Restore is an oral capsule built for general cellular energy support — not a topical product, and not an eczema treatment, since that specific research hasn't reached human oral-supplement trials. Each 2-capsule serving delivers 500 mg of Nicotinamide Riboside Chloride, one of the two most-researched NAD+ precursors, within the dose range used in published human trials, alongside 150 mg trans-resveratrol and 50 mg quercetin, polyphenols studied alongside NAD+ pathways for cellular health support. 10 mg of galactomannans from fenugreek is included to support absorption.
Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
NAD+ and eczema has a real, mechanistically detailed positive finding behind it — but it's topical NMN in mice, not an oral supplement tested in people, and those are two very different products with two very different levels of evidence. For actual eczema management, moisturizers, dermatologist-guided topical treatments, and trigger avoidance remain the evidence-based foundation. Related reading: NAD+ and skin aging and NAD+ and inflammation.
References
- Gao JF, Tang L, Luo F, Zhang YY, Chen L, Ding H, Meng ZD. Nicotinamide mononucleotide ameliorates DNFB-induced atopic dermatitis-like symptoms in mice by blocking activation of ROS-mediated JAK2/STAT5 signaling pathway. Int Immunopharmacol. 2022;109:108812. PMID: 35533554.
- Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;71(1):116-132. PMID: 24813302.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.